Search clinical trials for: Placebo of Aprepitant

Total 181792 results

Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Participants (MK-0869-208)

Chemotherapy Induced Nausea and Vomiting
LEO Pharma

Completed

Topical Aprepitant in Prurigo Patients (iTAPP)

Pruritus

Germany
Sun Yat-sen University

Completed

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment (EGFR-TKIs)

Non-small Cell Lung Cancer

China
University Hospital, Brest

Recruiting

Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms (APHYPAP)

Myeloproliferative Disorder | Aquagenic Pruritus

France
University of Virginia
National Institute on Drug Abuse (NIDA)

Completed

Medications Development for the Treatment of Cannabis Related Disorders (MTC)

Cannabis Dependence | Nicotine Dependence | Marijuana Dependence | Cannabis Abuse | Nicotine Withdrawal

United States
University Hospital Inselspital, Berne

Recruiting

Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery. (DDA-PONV)

Postoperative Nausea and Vomiting | Bariatric Surgery

Switzerland
Duke University
Merck Sharp & Dohme LLC

Completed

A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

Pancreatitis

United States
Dartmouth-Hitchcock Medical Center

Completed

The Role of Substance P on Perception of Breathlessness During Resistive Load Breathing (SP-RLB)

Chronic Obstructive Pulmonary Disease

United States
University Hospital, Rouen

Completed

Effects of Substance P Antagonists on Adrenal Secretion (APHOS)

Healthy Volunteers

France
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-073)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

Major Depressive Disorder
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals. 375 mg Dose

HIV Infection

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Bioequivalence of Aprepitant and Fosaprepitant and the Effect of Food on Aprepitant Bioavailability (0869-165)

Chemotherapy-Induced Nausea and Vomiting
Heron Therapeutics

Terminated

Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)

COVID-19

United States
Merck Sharp & Dohme LLC

Completed

Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-068)(COMPLETED)

Major Depressive Disorder
Merck Sharp & Dohme LLC

Completed

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-060)(COMPLETED)

Major Depressive Disorder
Gynecologic Oncology Associates
Merck Sharp & Dohme LLC

Completed

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

Ovarian Cancer | Uterine Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)

Post-operative Nausea | Post-operative Vomiting
University of Pennsylvania

Completed

Decreasing the Incidence of Post-Operative Nausea and Vomiting (PONV) in Bariatric Patients (PONV)

Nausea | Vomiting

United States
University of Pennsylvania
National Institute on Drug Abuse (NIDA)

Completed

HBPL Study of the Impact of the NK1 Antagonist Aprepitant

Alcohol Dependence | Cocaine Dependence

United States
The Affiliated Hospital of Qingdao University

Not yet recruiting

Comparative Pharmacokinetic Study of Aprepitant Injection in Humans

Healthy
The Hospital for Sick Children

Completed

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers

Chemotherapy-induced Nausea and Vomiting

Canada
Uppsala University Hospital

Completed

Treatment of Chemotherapy-induced Nausea and Vomiting

Nausea | Vomiting

Sweden
Dartmouth-Hitchcock Medical Center

Completed

Differentiating the Effects of Substance P and Beta-endorphin

Chronic Obstructive Pulmonary Disease

United States
Drexel University College of Medicine
Merck Sharp & Dohme LLC

Completed

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Nausea | Vomiting

United States
IWK Health Centre

Not yet recruiting

Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery

Anesthesia | Spinal Fusion | Nausea and Vomiting, Postoperative
Sharon Walsh
National Institute on Drug Abuse (NIDA); Merck Sharp & Dohme LLC

Completed

Aprepitant Effects on Oxycodone Response

Narcotic Abuse

United States
University Hospital, Rouen

Unknown

Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin (APHOS-02)

Hypertension | Type 2 Diabetes

France
University of Nebraska

Withdrawn

Comparison of Adding EMEND to PONV/PDNV Treatment Regimen

Postoperative Nausea and Vomiting

United States
Nuformix Technologies Limited

Completed

Relative Bioavailability of NXP001 Compared to Emend® in Healthy Volunteers

Healthy

United Kingdom
The Scripps Research Institute
National Institute on Drug Abuse (NIDA)

Completed

Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence

Alcohol Dependence | Cannabis Dependence | Alcohol Use Disorder | Cannabis Use Disorder

United States
Pfizer

Completed

A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers

Healthy

United States
Scott and White Hospital & Clinic
Merck Sharp & Dohme LLC

Completed

Combination Antiemetic Regimen for Prevention of PONV in Breast Surgery Patients

Postoperative Nausea and Vomiting

United States
Biogen

Terminated

Natalizumab (Tysabri) Re-Initiation of Dosing (STRATA)

Relapsing-Remitting Multiple Sclerosis

Finland, Germany, Spain, Belgium, Italy, Canada, France, New Zealand, Israel, Hungary, Greece, Australia, Netherlands, United Kingdom, Denmark, Ireland, Sweden, Poland, Czech Republic, Switzerland, Turkey
The Hospital for Sick Children

Terminated

Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents

Nausea | Vomiting | Chemotherapy

Canada
Merck Sharp & Dohme LLC

Completed

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Breast Neoplasms | Nausea | Vomiting
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer (NRR)

Breast Cancer | Nausea and Vomiting

United States
Karolinska University Hospital
Ministry of Health and Social Affairs, Sweden; County of Stockholm

Unknown

Ability of Aprepitant to Block Opioid Reward in Non-Dependent Opiate Abusers

Substance-Related Disorders | Opioid-Related Disorders | Heroin Dependence

Sweden
Merck Sharp & Dohme LLC

Completed

Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)

Chemotherapy-induced Nausea and Vomiting (CINV)
Sichuan Cancer Hospital and Research Institute

Not yet recruiting

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Gynecological Tumor

China
Multicenter Clinical Study Group of Osaka, Colorectal...

Completed

Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial

Colorectal Cancer

Japan
Merck Sharp & Dohme LLC

Completed

Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)

Vomiting
Kangdong Sacred Heart Hospital
Astellas Pharma Korea, Inc.; The Catholic University of Korea

Completed

Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone (RAPA)

Cancer | Tumors

Korea, Republic of
National Institute of Diabetes and Digestive and...

Completed

Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial (APRON)

Gastroparesis

United States
Vanderbilt University Medical Center

Terminated

Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome

Sezary Syndrome | Pruritus

United States
University of Pennsylvania
National Institute of Mental Health (NIMH)

Completed

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

HIV Infections

United States
Mayo Clinic

Completed

Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying

Healthy

United States
Hunan Province Tumor Hospital

Completed

Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers

Carcinoma, Non-small Cell Lung

China

Search clinical trials for: Placebo of Aprepitant

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations